The short answer
Discuss concentrated green tea extract with your prescriber before combining it with valproate. A large trial found more liver-enzyme elevations with a high-dose extract, and valproate has its own liver warning. The added risk of taking them together has not been measured.
What this answer covers
Concentrated Camellia sinensis leaf extract. Findings from the studied extract are not treated as evidence about ordinary brewed tea or a universal safe-dose cutoff.
- Supplement or preparation
- Camellia Sinensis Leaf Extract
- Medication ingredient
- valproate
What the trial found
In a one-year trial of 1,075 postmenopausal women, an extract supplying 843 mg of EGCG daily was associated with liver-enzyme elevations in 6.7% of recipients, compared with 0.7% taking placebo.
What the trial did not show
Overall adverse-event and serious-adverse-event frequencies were not significantly different between groups, and most events were mild and transient. Even so, some liver-enzyme events were serious. The trial does not tell us the risk in a person also taking valproate.
Extract strength and timing matter to the assessment
Bring the amount of extract and EGCG on the label to your clinician. The study does not identify a dose below which the combination is proven safe, and it does not establish that spacing the products prevents liver injury. Ordinary brewed tea was not the tested product.
Review use and symptoms with your clinician
Bring the product label and your dose and duration of use to your prescriber. Valproate requires liver monitoring, especially early in treatment. Seek prompt medical assessment for new loss of appetite, vomiting, marked weakness or unusual lethargy. Do not abruptly stop an anticonvulsant prescribed for epilepsy; medication decisions need your treating team.
Evidence and practical considerations
Side effects & toxicity
Concentrated green tea extract and valproate each have liver-safety concerns; direct evidence quantifying the combination was not identified.
- Exact scope
- Concentrated Camellia sinensis leaf extract. Findings from the studied extract are not treated as evidence about ordinary brewed tea or a universal safe-dose cutoff. with Oral valproate active moiety; label evidence is from oral valproic acid capsules, with Depakote exposure identified separately where relevant.
- Medication form and route
- oral valproate; supplement route as specified in source and scope
- Timing or duration
- No safe co-use duration or protective spacing interval established.
What remains uncertain
- The randomized trial studied one high-dose extract in postmenopausal women without a valproate comparison.
Factors that may matter: existing liver disease; concentrated extract; first six months of valproate treatment.
Read the supporting source summaries
Source 1: current oral product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral valproic acid capsules.
Label warns of potentially fatal liver injury, especially during the first six months, and thrombocytopenia/coagulation abnormalities. It recommends baseline and follow-up liver and blood assessments. P450 oxidation is a minor metabolic pathway. Aspirin increased free valproate fraction in six pediatric patients; the study is aspirin-specific.
How this applies: Medication risk and identity context for RxCUI 40254 valproate; oral active-moiety bridge only.
Not a study of any of these botanical combinations. Active-moiety identity does not establish interchangeable doses, release kinetics or routes. Aspirin results do not establish salicin or methyl salicylate effects.
Source 2: randomized double-blind placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 1075 postmenopausal women in the Minnesota Green Tea Trial.
ALT elevation occurred in 36 extract recipients (6.7%) versus four placebo recipients (0.7%). Overall adverse-event and serious-adverse-event frequencies were not significantly different; most events were mild and transient. ALT-related serious adverse events occurred in 1.3% of extract recipients.
How this applies: Supports concentrated green tea extract liver risk separately from the valproate label, not demonstrated combined toxicity.
Not a valproate co-use trial. One concentrated extract and population; no universal dose threshold or brewed-tea equivalence. Abstract only.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original sources checked and exact-pair evidence package prepared; no clinical review asserted. | |
| Research summary published |
Article revision: 410a0b60c2d6f0c4
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.